NUVL – Nuvalent Inc

NUVL — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

10.98

Margin Of Safety %

Put/Call OI Ratio

0.86

EPS Next Q Diff

0.21

EPS Last/This Y

0.35

EPS This/Next Y

1.52

Price

96.61

Target Price

143.94

Analyst Recom

1.17

Performance Q

-8.6

Upside

-311.8%

Beta

1.32

Ticker: NUVL

14 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-03-09	NUVL	102.26	0.87	0.04	1100
2026-03-10	NUVL	102.21	0.87	0.04	1100
2026-03-11	NUVL	100.14	0.84	0.00	1122
2026-03-12	NUVL	98	0.84	0.00	1121
2026-03-13	NUVL	98	0.84	0.00	1121
2026-03-17	NUVL	98.98	0.83	0.00	1127
2026-03-18	NUVL	97.46	0.85	5.00	1113
2026-03-19	NUVL	97.05	0.85	5.00	1113
2026-03-20	NUVL	94.78	0.85	5.00	1113
2026-03-23	NUVL	96.37	0.77	0.00	975
2026-03-24	NUVL	96.13	0.77	0.00	975
2026-03-25	NUVL	98.04	0.77	3.88	975
2026-03-26	NUVL	98.12	0.87	0.25	1047
2026-03-27	NUVL	95.82	0.86	999.99	1051
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

14 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-02-27	NUVL	101.88	-36.8	-128.2	-5.56
2026-03-02	NUVL	101.33	-36.8	29.6	-5.56
2026-03-03	NUVL	100.16	-12.8	32.3	-5.48
2026-03-04	NUVL	102.76	-12.8	16.3	-5.48
2026-03-05	NUVL	100.19	-10.9	37.5	-5.40
2026-03-06	NUVL	99.36	-10.9	30.9	-5.40
2026-03-09	NUVL	102.29	-10.9	30.1	-5.40
2026-03-10	NUVL	102.24	-10.9	43.6	-5.40
2026-03-11	NUVL	100.07	-10.9	52.8	-5.40
2026-03-12	NUVL	97.98	-10.9	52.6	-5.40
2026-03-13	NUVL	97.90	-10.9	43.8	-5.40
2026-03-17	NUVL	98.93	-10.9	46.0	-5.50
2026-03-18	NUVL	97.47	-10.9	74.5	-5.50
2026-03-19	NUVL	97.06	-10.9	76.2	-5.50
2026-03-20	NUVL	94.77	-10.9	85.9	-5.50
2026-03-23	NUVL	96.37	-10.9	79.1	-5.50
2026-03-24	NUVL	96.15	-10.9	80.1	-5.50
2026-03-25	NUVL	97.99	-10.9	72.3	-5.50
2026-03-26	NUVL	98.17	-10.9	71.5	-5.50
2026-03-27	NUVL	96.61	-10.9	78.1	-5.50
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

15 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-03-06	NUVL	-4.61	11.19	11.91
2026-03-09	NUVL	-4.32	11.22	10.94
2026-03-10	NUVL	-4.43	11.22	10.94
2026-03-11	NUVL	-4.43	11.22	10.67
2026-03-12	NUVL	-4.43	11.22	10.67
2026-03-13	NUVL	-4.41	11.22	10.67
2026-03-17	NUVL	-4.53	11.25	10.67
2026-03-18	NUVL	-4.44	11.25	10.67
2026-03-19	NUVL	-4.44	11.25	10.67
2026-03-20	NUVL	-4.44	11.25	10.67
2026-03-23	NUVL	-4.44	11.25	10.67
2026-03-24	NUVL	-4.44	11.25	10.67
2026-03-25	NUVL	-4.44	11.25	10.98
2026-03-26	NUVL	-4.53	11.25	10.98
2026-03-27	NUVL	-4.53	11.25	10.98
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

15 items 1 of 1

Last Quarter Act. EPS

-1.58

Avg. EPS Est. Current Quarter

-1.31

Avg. EPS Est. Next Quarter

-1.37

Insider Transactions

-4.53

Institutional Transactions

11.25

Beta

1.32

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

14.9

Max Drawdown 5-Year %

Target Price

143.94

P/E

Forward P/E

PEG

P/S

P/B

6.06

P/Free Cash Flow

EPS

-5.85

Average EPS Est. Cur. Y

-5.5

EPS Next Y. (Est.)

-3.98

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.9

Return on Equity vs Sector %

-61.4

Return on Equity vs Industry %

-45.2

EPS 1 7Days Diff

-0.1

EPS 1 30Days Diff

0.1

EBIT Estimation

78.1

◆ NUVL Healthcare

$96.66

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

14/20

Pullback

19/25

Volume

7/15

Valuation

7/20

TP/AR

2/10

Options

3/10

RSI

42.5

Range 1M

24.2%

Sup Dist

0.2%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

9/25

Growth

9/30

Estimates

1/20

Inst/Vol

7/15

Options

4/10

EPS Yr

4.9%

EPS NY

23.7%

52W%

71.1%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +48.9% upside

Quality

2/30

Valuation

10/30

Growth

7/25

Stability

8/10

LT Trend

1/5

Upside

+48.9%

Quality

Nuvalent, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 228

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the Phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; Neladalkib (NVL-655), a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the Phase 2 portion of the ALKOVE-1 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR that is in Phase 1a/1b clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

NUVL

Latest News

—

Caricamento notizie per NUVL…

stock quote shares NUVL – Nuvalent Inc Stock Price stock today

news today NUVL – Nuvalent Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch NUVL – Nuvalent Inc yahoo finance google finance

stock history NUVL – Nuvalent Inc invest stock market

stock prices NUVL premarket after hours

ticker NUVL fair value insiders trading

NUVL – Nuvalent Inc

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: NUVL

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y